|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 36, 37808-37814, September 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


¶
From the
Department of Molecular Ophthalmology, Lions Eye Institute and the
Centre for Ophthalmology and Visual Science, University of Western Australia, 2 Verdun Street, Nedlands, Western Australia 6009, Australia
The regulation of vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis, is controlled primarily through the interactions of control elements located within the 5'- and 3'-untranslated regions, many of which are yet to be described. In this study we examined the 5'-untranslated region of human VEGF for control elements with the aim of regulating expression both in vitro and in vivo using oligonucleotide gene therapy. A potential control element was located, two sense oligonucleotides (S1 and S2) were designed based on its sequence, and a third oligonucleotide (S3) was designed as a control and mapped to the 16 base pairs immediately upstream. Retinal cells cultured in the presence of S1 and S2 resulted in a 2-fold increase of VEGF protein and a 1.5-fold increase in mRNA 24 h post-transfection whereas S3 had no significant effect (p > 0.05) compared with controls. Subsequent reporter gene studies confirmed the necessity of this element for up-regulation by S1. Further in vivo studies showed that S1 and S2 mediated an increase in VEGF protein in a rodent ocular model that resulted in angiogenesis. In addition to providing insight into the regulation of the vascular endothelial growth factor, the use of these oligonucleotides to stimulate vascular growth may prove useful for the treatment of ischemic tissues such as those found in the heart following infarct.
Received for publication, January 5, 2004 , and in revised form, May 14, 2004.
* Portions of this work were funded by the National Health and Medical Research Council of Australia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 61-9381-0735; Fax: 61-9381-0700; E-mail: robert{at}lei.org.au.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |